+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

How progestins influence the cardiovascular effect of hormone replacement therapy



How progestins influence the cardiovascular effect of hormone replacement therapy



Gynecological Endocrinology 15(Suppl. 6): 9-17



Hormone replacement therapy aims to protect against osteoporosis and alleviate fastidious menopausal symptoms such as hot flushes, depression, sleep disturbances and vaginal dryness. In view of the acknowledgement of estrogen deficiency as a major trigger for the acceleration of cardiovascular risk after menopause, hormone replacement therapy may also be proposed as a substantial beneficial cardioprotective agent. The effects of progestins on lipoprotein profile and vasomotor tone are dependent on the chemical structure and the scheme of administration of progestins, with androgenic progestins and cyclical therapy having a potential detrimental effect. Prospective primary and secondary prevention studies, however, suggest that the adjunct of non-androgenic progestins to estrogen therapy is at least as effective as estrogen replacement therapy in reducing cardiovascular mortality and morbidity. Data from recent randomized secondary prevention studies have to be viewed with caution.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046280854

Download citation: RISBibTeXText

PMID: 12227881


Related references

How progestins influence the cardiovascular effect of hormone replacement therapy. Gynecological Endocrinology 15(S6): 9-17, 2001

Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials?. Arteriosclerosis Thrombosis and Vascular Biology 24(7): 1171-1179, 2004

The influence of progestins on normotensive and hypertensive menopausal women under hormone replacement therapy. Maturitas 27(Suppl. ): 162, 1997

Lipid profile during hormone replacement therapy: effect of different progestins?. Zentralblatt für Gynakologie 119(Suppl. 2): 1-6, 1997

The role of progestins in hormone replacement therapy. International Journal of Gynecology and Obstetrics 40(2): 178-179, 1993

The role of progestins in hormone replacement therapy. American Journal of Obstetrics and Gynecology 166(6 Pt 2): 1997-2004, 1992

Transdermal progestins in hormone replacement therapy. Annals of the new York Academy of Sciences 828: 352-357, 1997

Is bio-identical hormone replacement therapy safer than traditional hormone replacement therapy?: a critical appraisal of cardiovascular risks in menopausal women. Treatments in Endocrinology 5(6): 367-374, 2006

Estrogens and progestins in hormone replacement therapy in menopause. Recenti Progressi in Medicina 92(3): 209-212, 2001

Cardiovascular disease, menopause, and the influence of hormone replacement therapy. Progress in Clinical and Biological Research 320: 313-332, 1989

Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 3(3): 199-211, 2000

Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 3(3): 199-211, 2000

Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Reviews in Endocrine and Metabolic Disorders 3(3): 211-224, 2002

The relative effects of progesterone and progestins in hormone replacement therapy. Human Reproduction 15(Suppl. 1): 60-73, 2000

A comparison of the central effects of different progestins used in hormone replacement therapy. Maturitas 48(4): 456-462, 2004